Hyperosmolar Therapy in Intracerebral Hemorrhage (ICH): Indications & Timing

Background: Why ICH Causes Elevated ICP

1. Direct mass effect - the hematoma itself compresses surrounding brain
2. Secondary injury - perihematomal edema, hydrocephalus from intraventricular extension, and blood product-mediated cellular injury

Specific Indications: When to Start

1. Clinical Signs of Transtentorial (Uncal) Herniation

• Unilateral fixed and dilated pupil (CN III compression)
• Sudden GCS drop of ≥2 points that is not explained by sedation or metabolic causes
• Cushing's triad: hypertension + bradycardia + irregular respirations (late sign, means severe herniation)
• Decerebrate or decorticate posturing (bilateral extensor or flexor posturing)
• Bilateral fixed pupils (late, very ominous)

2. ICP >20-22 mmHg on Invasive Monitoring

• When an ICP monitor (ventriculostomy or intraparenchymal probe) is in place, the threshold for treatment is ICP >20 mmHg (some guidelines say >22 mmHg)
• Concurrent target: maintain Cerebral Perfusion Pressure (CPP) = 50-70 mmHg (CPP = MAP - ICP)
• If ICP monitoring shows refractory elevation not responding to first-line measures (head of bed elevation, CSF drainage, mild hyperventilation), hyperosmolar therapy is escalated

3. Radiographic Mass Effect Without ICP Monitor

• Significant midline shift (typically >5 mm) with declining neurological exam
• Large hematoma with surrounding edema causing herniation on imaging
• Effacement of basal cisterns (indicates high ICP)
• Hydrocephalus from intraventricular extension (IVH) with declining consciousness - though EVD/ventriculostomy is preferred here

4. GCS ≤8 with Any of the Following (per AHA/ASA 2015 guidelines)

• Abnormal CT (hematoma, midline shift, IVH)
• Clinical evidence of transtentorial herniation
• Significant IVH or hydrocephalus These patients may be considered for ICP monitoring AND concurrent hyperosmolar therapy.

2022 AHA/ASA Guideline Recommendations (Key Points)

Key take-away from 2022 AHA: Hyperosmolar therapy is reactive, not prophylactic in ICH. Give it when there is an acute ICP crisis, not as a preemptive measure.

What NOT to Do

• Do not give prophylactically in stable patients without signs of elevated ICP - no proven outcome benefit (Greenberg et al., 2022 AHA/ASA guideline)
• Do not give in prehospital setting without confirmed signs of herniation - Sabiston Textbook notes it "has not shown benefit" when given prophylactically in the prehospital setting
• Do not use corticosteroids - harmful in ICH (unlike in brain tumors or meningitis)

Drug Specifics

Mannitol

• Dose: 0.5-1 g/kg IV bolus (typically 20% mannitol), then 0.25-1 g/kg every 4-6 hours
• Monitor: Serum osmolality (keep <320 mOsm/kg to avoid renal toxicity), osmolar gap <20
• Onset: 15-30 minutes; duration 4-6 hours
• Caution: Causes volume depletion; avoid in hypotension or renal failure

Hypertonic Saline (HTS)

• Dose: 23.4% NaCl 30 mL bolus via central line for acute herniation; 3% NaCl 150-250 mL infusion for ongoing ICP management
• Target serum Na+: 145-160 mEq/L (upper limit per guidelines: 155-160 mEq/L)
• Advantage over mannitol: Expands intravascular volume, may be preferred in hypotension
• Caution: Hyperchloremic acidosis with prolonged use; central pontine myelinolysis risk with rapid overcorrection in chronic hyponatremia

Stepwise ICP Management in ICH (Tiered Approach)

Summary

1. Acute herniation signs - treat immediately, do not wait
2. ICP >20-22 mmHg on monitor that persists after basic measures
3. GCS ≤8 + large hematoma/midline shift/IVH on CT - often empirically started pending monitoring
4. Progressive neurological deterioration (dropping GCS ≥2 points) without another explanation